11/15
09:47 am
ostx
OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
High
Report
OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
11/4
07:00 am
ostx
OS Therapies to Present at The Spartan Capital Investor Conference
Low
Report
OS Therapies to Present at The Spartan Capital Investor Conference
10/30
08:51 am
ostx
Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30
Low
Report
Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30
10/28
04:44 pm
ostx
OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors
Medium
Report
OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors
10/24
08:46 am
ostx
OS Therapies to Present at the LD Micro Main Event XVII
Low
Report
OS Therapies to Present at the LD Micro Main Event XVII
10/17
09:22 am
ostx
OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
Neutral
Report
OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
10/3
08:00 am
ostx
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit
Medium
Report
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit
9/13
08:09 am
ostx
OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates
Low
Report
OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates
9/11
08:15 am
ostx
OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models
High
Report
OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models
9/5
10:25 am
ostx
OS Therapies Inc (NYSE: OSTX) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
Low
Report
OS Therapies Inc (NYSE: OSTX) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
9/5
08:22 am
ostx
OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference
Low
Report
OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference
8/29
07:53 am
ostx
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
Low
Report
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
8/24
05:57 am
ostx
OS Therapies Inc (NYSE: OSTX) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
Medium
Report
OS Therapies Inc (NYSE: OSTX) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.